📢 A brand new publication from GHI steering committee member, Ken Shadlen, w/ Margaret Kyle and Bhaven Sampat, in Health Affairs Scholar:
'TRIPS, pharmaceutical patents, and generic competition in India'
đź“Ž Read the open-access piece here: bit.ly/3N28FDG
LSE Global Health Initiative
Ken Shadlen and co authors examine how a key TRIPS transitional rule, excluding drugs with pre-1995 global priority filings from patent eligibility in India, shaped “primary” patents and generic competition.
New (open access) in Health Affairs Scholar: academic.oup.com/healthaffair...
AbstractIntroduction. India introduced pharmaceutical patents in response to the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreeme
